Difference between revisions of "Lenalidomide (Revlimid)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to [[Thalidomide (Thalomid)]]; mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.<ref name="insert">[http://www. | + | Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to [[Thalidomide (Thalomid)]]; mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.<ref name="insert">[http://www.celgene.com/content/uploads/revlimid-pi.pdf Lenalidomide (Revlimid) package insert]</ref><ref>[[Media:Lenalidomide.pdf|Lenalidomide (Revlimid) package insert (locally hosted backup)]]</ref><ref>[http://revlimid.com/ Revlimid manufacturer's site]</ref><ref name="revassist">[https://www.celgeneriskmanagement.com/REMSPortal/rems/portal/REMSPortal.portal Revlimid REMS program]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 25: | Line 25: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://hemonc.org/wiki/Lenalidomide_(Revlimid) Lenalidomide (Revlimid) package insert]<ref name="insert"></ref> |
*[http://www.revlimid.com/wp-content/uploads/medication-guide.pdf Lenalidomide (Revlimid) patient medication guide]<ref>[http://www.revlimid.com/wp-content/uploads/medication-guide.pdf Lenalidomide (Revlimid) patient medication guide]</ref> | *[http://www.revlimid.com/wp-content/uploads/medication-guide.pdf Lenalidomide (Revlimid) patient medication guide]<ref>[http://www.revlimid.com/wp-content/uploads/medication-guide.pdf Lenalidomide (Revlimid) patient medication guide]</ref> | ||
*[http://chemocare.com/chemotherapy/drug-info/Lenalidomide.aspx Lenalidomide (Revlimid) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Lenalidomide.aspx Lenalidomide (Revlimid) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/Lenalidomide.aspx Lenalidomide (Revlimid) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Lenalidomide.aspx Lenalidomide (Revlimid) patient drug information (Chemocare)]</ref> | ||
| Line 34: | Line 34: | ||
*6/29/2006: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm FDA approved] for treatment of patients with "[[Multiple myeloma |multiple myeloma (MM)]], in combination with [[Dexamethasone (Decadron) | dexamethasone]], in patients who have received at least one prior therapy.]<ref name="insert"></ref> | *6/29/2006: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm FDA approved] for treatment of patients with "[[Multiple myeloma |multiple myeloma (MM)]], in combination with [[Dexamethasone (Decadron) | dexamethasone]], in patients who have received at least one prior therapy.]<ref name="insert"></ref> | ||
*6/5/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm FDA approved] for patients with "[[Mantle cell lymphoma |mantle cell lymphoma (MCL)]] whose disease has relapsed or progressed after two prior therapies, one of which included [[Bortezomib (Velcade) | bortezomib]]."<ref name="insert"></ref> | *6/5/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm FDA approved] for patients with "[[Mantle cell lymphoma |mantle cell lymphoma (MCL)]] whose disease has relapsed or progressed after two prior therapies, one of which included [[Bortezomib (Velcade) | bortezomib]]."<ref name="insert"></ref> | ||
| − | *2/22/2017: FDA approval expanded "as maintenance therapy for patients with [[multiple myeloma]] following autologous stem cell transplant." | + | *2/22/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm FDA approval expanded] "as maintenance therapy for patients with [[multiple myeloma]] following autologous stem cell transplant." |
==Also known as== | ==Also known as== | ||
Revision as of 06:54, 24 February 2017
General information
Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to Thalidomide (Thalomid); mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.[1][2][3][4]
Route: PO
Extravasation: n/a
- Use of Lenalidomide (Revlimid) requires participation the Revlimid REMS program.[4]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Cutaneous T-cell lymphoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Light-chain (AL) amyloidosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Multiple myeloma
- Myelodysplastic syndrome
- Myelofibrosis
- Peripheral T-cell lymphoma
- Plasma cell leukemia
- Transformed lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Lenalidomide (Revlimid) package insert[1]
- Lenalidomide (Revlimid) patient medication guide[5]
- Lenalidomide (Revlimid) patient drug information (Chemocare)[6]
- Lenalidomide (Revlimid) patient drug information (UpToDate)[7]
History of changes in FDA indication
- 12/28/2005: FDA approved for patients with "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities."[1]
- 6/29/2006: FDA approved for treatment of patients with "multiple myeloma (MM), in combination with dexamethasone, in patients who have received at least one prior therapy.][1]
- 6/5/2013: FDA approved for patients with "mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib."[1]
- 2/22/2017: FDA approval expanded "as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant."
Also known as
CC-5013, IMiD-1, NSC-703813
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Lenalidomide (Revlimid) package insert
- ↑ Lenalidomide (Revlimid) package insert (locally hosted backup)
- ↑ Revlimid manufacturer's site
- ↑ 4.0 4.1 Revlimid REMS program
- ↑ Lenalidomide (Revlimid) patient medication guide
- ↑ Lenalidomide (Revlimid) patient drug information (Chemocare)
- ↑ Lenalidomide (Revlimid) patient drug information (UpToDate)
Categories:
- Drug index
- Chemotherapy
- Oral chemotherapy
- Immunomodulatory drugs (IMiDs)
- Adult T-cell leukemia-lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Cutaneous T-cell lymphoma medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Multiple myeloma medications
- Myelodysplastic syndrome medications
- Myelofibrosis medications
- Peripheral T-cell lymphoma medications
- Plasma cell leukemia medications
- Transformed lymphoma medications
- Waldenström macroglobulinemia medications
- REMS program
- Drugs FDA approved in 2005